µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ f+/AD
d%y)/5
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ }'y=JV>l
P,|%7'? Y
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ @MS}tZ5
&.zG?e.
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© w$X"E*~>8
k
_E
Jg;(
1. CD4 s7A3CY]->
(V:z7
2. T cell receptor(TCR) 8gQg#^,(t
3N(5V;ti
3. immunoglobulin superfamily (IgSF) y h
ps DY}y\"
4. selectin :7,j%ELic
w)#Lu/
5. anti-idiotypic antibody (¦ÁId) k
q{PM-]l
b6`_;Z
6. major histocompatibility complex(MHC) o =oXL2}
|XDbf3^6
7. immunotolerance WE-cq1)
tJ"8"T#6Vr
8. biological reponse modifier(BRM) 88@" +2
FZvh]ZX
9. immune reponse gene (Ir gene) Y#VtZTcT
{Wi)/B}
10. reshaped antibody (or reconstituted antibody) S%^*h{9u"
0eGz|J*7
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,ln=kj
_d[4EY
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 1}7Q2Ad w
R{3?`x!fY
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? O`;e^PhN
S'h{["P~
0
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Z[,A>tJ
TtWE:xE
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? ^Fn~@'
xJ);P.
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) &OMe'P
!.EDQ1k
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ x%Fy1.
J)o =0i>*
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 38gHM9T
xh
G-DvM6T
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? %>mB"Y,
ta*6xpz-\Q
¡¡ #~I.F4
k-;A9!^h
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ eyIbjgpV
GGWdMGI/
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? a3Fe42G2c|
VQV%1f
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? sT<XZLu
R #\o*Ta
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ %8]~+#]p
?j:g. a+U
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ }u
`~lw(Z
%
k}+t3aF
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ }Y=X{3+~.
a^>e|Eq|
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© "c2{n,
h%[1V
1. CD8 vyXL F'L
)C^@U&h&
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) so]p1@K
FhAYk
3. immunoglobulin fold(Ig fold) d+iV19 #i
}[O/u <Z
4. cadherin (Ca-dependent cell adhesion moleculers) :%2uZ/cG(
k "Qr
5. idiotype-anti-idiotypic antibody immune network theory l2ww3)Z
D:DtP6
6. HLA class II antigen }u&,;]
1!"iN~
7. complementarity-determining region (CDR) s^lm
81;
C%T$l8$
8. perforin(or pore-forming protein ,PFP) 7c>{og6
!`S61~gE
9. high affinity IL-2 receptor L`@)*x)~R
Zf*DC~E_
10. artificial active immunization =t!$72g\
w
NtPh&
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© wVac6q
#Ab,h#f*7
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ&|#z" E^-
bQBYzvd
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 &:}}T=@M1
M?G
4k]
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ T.B}k`$
r;'Vy0?AL
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԡ¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ .~jn
N
rG"QK!R5
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) ~9h/{$
v3Xt<I=4y
1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ y1*z,"dx
MB3 0.V/\
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? h6uv7n~4
rwCjNky!
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ^E| {i]j#f
Y&y5^nG
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ganXO5T$
:j4i(qcF
¡¡ ^_o9%)RL(
g4CdzN~
h&Q9
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ +t`QHvx
v
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ I$vM )+v=
p&<X&D
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ x"xtILrI
xK;WJm"
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© E])X$:P?
u>I;Cir4
1. immunoglobulin gene rearrangement F G5e{
:.%Hu9=GL
2. the common chain of cytokine receptor (or a cytokine receptor ;zZGV4Qc~
Ow7}&\;^-
subunit shared by some cytokine receptors) '@Q
aeFm
IsjD-t
3. flow cytometry(FCM) Gkq<?q({t
2gC.Z:}
4. carrier effect glvtumv
// \UthOT
5. positive selection of T lymphocytes in thymus |Lz:i+;
|[]"{Eo"}
6. mouse TH1(Th1) and TH2(Th2) subsets 5
LZ+~!2+
4lqow
g0
7. perforin (pore-forming protein ,PFP) ,'69RL?-Wg
L8zY?v(bG
8. ADCC(antibody-dependent cell-mediated cytotoxicity) jSyF]$"
"jyh.@<
9. SH-2(src-homology region 2) HBc^[fJ^-
jLEwFPz
10. Ab2¦Â (internal image) 8>sToNRNe
8yDu(.Q
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© =os%22*
6k=ink-/
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? _=.f+1W
N?'V,p
0=
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? -H%806NAX7
'b*
yYX<
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠN:y3tpG
)&j4F)
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ 5$e|
@/(0
$Qv+*%c
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ[kyF |3k~
f3+@u2Pv
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) C#<:x!
IQS:tL/
ÃâÒßѧרҵ£º <.0-K_
(= H%VXQH
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ (o1
*7_]e
L44/eyrp
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 8xQ5[Ov
*N .f_s
´«È¾²¡Ñ§×¨Òµ£º af61!?K
3%]%c6
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ S=>54!{`x
%&+j(?9
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ *v[WJ"8@
)v-sde\
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ +zQ
a"Ep*
,%#FK|
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? .$/Su3]K/
W>Eee?
,BCtNt(
8,p nm
Fu0 dYN
sv0)sL
wRn]
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ `H6-g=C
N/QTf1$
ÃâÒßѧÊÔÌâ \WG6\Zg0A
cF9bSY_Eh
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© P08=?
-t_t3aU|
1. Fas(CD95)/FasL n}MW# :eJe
79|=y7i#
2. common chain of cytokine receptor rmS.$h@7 m
.5*h']iFr1
3 . TCR/CD3 complex {<{
O!
ES[H^}|Gi
4. negaive selection of thymocytes m?DI]sIv#
0b%"=J2/p.
5. artificial active immune 45` i
h
I.@!$~=
6. anti-idiotypic T
22tZp
r>4HF"Nm
7. IgSF Atc<xp
|
+osEHC
8. Integrin r(;sX
oc+TsVt
9. chemokine fgrflW$
NUBf>~_}
10. B7/CD28 Vmq:As^a
E9e|+$
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© %M8m 8
)
UnSi= uj
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ _
L}k.
m)l<2`CM
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 iNj*Gj
'
sb&xj`d
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Qh*"B
{m%]`0
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ gR7in!8
mX8k4$z
n~ w.\939@
sz;B-1^6
?'>pfU
CK[w0VCT
dsJMhB_41U
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ s{g^K#BoFi
7]\_7L
|>]
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ckDWY<@v
:Vdo.uUa
1. B7/CD28 }EJAC*W,
O4`am:@
2. Th1 subset dWKjVf
+\s32o
zg
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© O+f'Ql
Y\7WCaSgi
4. antibody affinity maturation ]2zzY::Sd=
76IjM4&a
5. AP-1 )By#({O
Nw3K@Ge
6. single chain variable fragment£¨ScFv£© F7!q18ew
PxAUsY
7. NK cell receptor ta;q{3fe
[]L
yu
8. Zinkernagel-Doherty phenomenon RyuI2jEy
0&21'K)pW
9. Ig fold Q[6<Y,}(pd
zWA~0l.2
10. CD40/CD40L +.3,(l
BN]{o(EB
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© W)LtnD2 w
[TaYNc!\
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ j&y>?Y&Sb
^J-"8%
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 7eU
|iDYo
yt5'2!jc
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ o0&pSCK
HYcwtw6
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ KQulz
)4O* D92
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ IEj=pI
2;`F`}BA
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ gPf^dGi7t
kf-/rC)>
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ d{FD.eI0
(
L ]C
uzO3 _.4Y
LVAnZ'h/|
@7z_f!'u
N1l&$#Fr!s
$g @-WNe
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ "v[?`<53^l
r4wnfy
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© .4cOMiG
!<AY0fpY
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #fkOm
Y7X
V+MhS3VD
1.Co-stimulators (or co-stimulating molecules) >G<.^
~o
Y:3\z?oV[
2.NK-kB 38 HnW
mj^]e/s%
3.Immunoglobulin superfamily @K}8zMmW#
X!=*<GF)
4.antigen-presenting cell (APC) lV)SOs$
t^(#~hx
5.death domain BdYl
sYp
@"$rR+r'
6.CCR and CXCR [-*8S1
ckg8x&Z
7.Lectin (or mitogen) F?!
ab-MEN`5
8.Clusters of differentiation, CD) y|0I3n]e
Pln*?o
9.B7 family nbM7 >tnsk
RI2Or9.
10.Cytotoxic T lymphocyte, CTL) DfL>fk
Uk0]A
11.IL-15 and IL-15 receptor (IL-15R) ~!G&K`u
8G0DuMI5
12.MHC restriction va_TC!{;
O&c~7tM%
13.Affinity-chromatography <78LB/:
xFcRp2W9R
14.Cyctosprin A, CsA NA`EG,2
S3( 2.c~
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) mK2M1r
bk#t+tuk
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© :/
yR
.O+qtk!
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 rH<iUiA?O
8(Y=MW;g
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ ZdJer6:Z}
i%R2#F7I
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌص㡣 Q hHexr6
`Y`QxU!d%
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© qt#a_F*rV
K)`\u7Bu
ÃâÒßѧרҵ£º u/h!i@_w[
.2jG
~_W[
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ )n[ oP%
:K)=Hf2y
Ïû»¯ÄÚ¿Æ£º @zJhJ'~Sl
t7%!~s=,M
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ B0:[3@P7
Bkn-
OG
ѪҺ²¡Ñ§×¨Òµ£º ly d[GfJ
<Dr*^GX>?
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ .+H8c.
USnKj_e
ezt_ct/Z
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ $rySz7NI
lxRzyx
(רҵ»ù´¡: ÃâÒßѧ) fWR]L47n
#_+T@|r
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) eXa a'bTx
6t5)r
lT
1. ADCC(antibody dependent cell-mediated cytotoxicity) >8V;:(nt
d0b--v/
2. »·æß¾úËØ(cyclosporin) #4{f2s[j6
[UI4YZu}
3. KIR(killer cell inhibitory receptor) [H#I:d-+\
P'D~Y#^
4. HLDA(human leucocyte differentiation antigen) ,>%AEN6N2
<?P UF,
5. Interleukin 18(IL-18) /h0<0b?i
3MC| O5R4
6. ÕûºÏËØ(integrin) ,z)7rU`
`}F=Zjy
7. Fas/FasL ij6M E6
Dd*T5A?
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Z{/C4" F
sp[nKo^
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) >ofS'mp
F5%-6@=
10. Th1/Th2 `4Z#/g
dH!k{3bL
11. »ùÒòÒßÃç(DNAÒßÃç) VVJhQ bP
#JZf]
rtp
12. chemokines and chemokine receptor +U^dllL7
*ZGQ`#1.X6
13. ÃâÒßÄÍÊÜ ]k{cPK
M!=v"C#
14. ¹²´Ì¼¤·Ö×Ó G4s!q1H
(H+'sf^h
15. ËÀÍö½á¹¹Óò(death domain) vsoj] R$C
I~"-
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) QE!cf@~n"
ms
;RJT2O'
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? u!nt0hS
xzMa[D4(
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠNEZF q?
% 9BC%w]y
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î cY#TH|M
;'tsdsu}
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ )J (ekfM
,i*^fpF`F"
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå z]P |%
|=38t8Ge&
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ Ko''G5+
9z_Gf]J~
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£